Entyvio

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process.** If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4**.**

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Drug Information:

*Strength/Measure*_____ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un

*Directions(sig)*_____ *Route of administration*_____

*Dosing frequency*_____

Send completed form to: Priority Partners Fax: 1-866-212-4756

Site of Service Questions:

A. Indicate the site of service requested:
- ❑ On Campus Outpatient Hospital (22)
- ❑ Off Campus Outpatient Hospital (19)
- ❑ Home (12), *skip to Criteria Questions*
- ❑ Office (11), *skip to Criteria Questions*
- ❑ Ambulatory Surgical Center (24), *skip to Criteria Questions*

B. Is the patient less than 18 years of age?
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No

C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.*** ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

D. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?
ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

E. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

G. Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

H. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?
ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation. ❑ Yes ❑ No

Clinical Criteria Questions:

1. Has the patient been diagnosed with any of the following?
   - ❑ Moderately to severely active Crohn's disease (CD)
   - ❑ Moderately to severely active ulcerative colitis (UC)
   - ❑ Immune checkpoint inhibitor-related diarrhea or colitis
   - ❑ Other _____
2. What is the ICD-10 code? _____
3. Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic disease-modifying anti-rheumatic drugs (DMARD) (e.g., Xeljanz)? ❑ Yes ❑ No
4. Is the patient currently receiving Entyvio? ❑ Yes ❑ No
5. What is the prescribed dose? Indicate mg and frequency.
   - ❑ Loading dose (if applicable) _____
   - ❑ Maintenance dose _____

Send completed form to: Priority Partners Fax: 1-866-212-4756

6. Is this request for continuation of therapy with the requested drug?
   ❑ Yes ❑ No *If No, skip to diagnosis section.*

7. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? *If Yes or Unknown, skip to diagnosis section.* ❑ Yes ❑ No ❑ Unknown

8. Has the patient achieved or maintained remission? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of remission.*** *If Yes, no further questions* ❑ Yes ❑ No

9. Has the patient achieved or maintained positive clinical response to treatment as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?
   ❑ Yes ❑ No

10. *If diagnosis is ulcerative colitis (UC) or Crohn's disease (CD),* which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response to therapy.***
    Indicate ALL that apply.
    ❑ Stool frequency
    ❑ Rectal bleeding
    ❑ Urgency of defecation
    ❑ C-reactive protein (CRP)
    ❑ Fecal calprotectin (FC)
    ❑ Endoscopic appearance of the mucosa
    ❑ Improvement on a disease activity scoring tool (e.g., Ulcerative colitis Endoscopic Index of Severity [UCEIS], Mayo Score)
    ❑ None of the above

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Ulcerative Colitis

11. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic disease modifying drug (e.g., Xeljanz) indicated for the treatment of moderately to severely active ulcerative colitis? ***ACTION REQUIRED: If Yes, please attach patient's chart notes, medical record documentation, or claims history of previous medications tried.*** *If Yes, no further questions* ❑ Yes ❑ No

12. Has the patient been hospitalized for acute, severe ulcerative colitis (e.g., continuous bleeding, severe toxic symptoms, including fever and anorexia)? ***ACTION REQUIRED: If Yes, please attach supporting chart notes or medical record documentation of hospitalization due to acute, severe ulcerative colitis.***
    If Yes, no further questions ❑ Yes ❑ No

13. Has the patient tried and had an inadequate response to at least one conventional therapy option? ***ACTION REQUIRED: If Yes, please attach patient's chart notes, medical record documentation, or claims history of previous medications tried, including response to therapy.***
    If Yes, indicate below and no further questions.
    ❑ Yes - Azathioprine (Azasan, Imuran)
    ❑ Yes - Corticosteroid (e.g., budesonide [Entocort, Uceris], hydrocortisone [Cortifoam, Colocort, Solu-Cortef, Cortef], methylprednisolone [Medrol, Solu-Medrol], prednisone)
    ❑ Yes - Cyclosporine (Sandimmune)
    ❑ Yes - Mesalamine (e.g., Asacol, Lialda, Pentasa, Canasa, Rowasa)), balsalazide, olsalazine
    ❑ Yes - Mercaptopurine (Purinethol)
    ❑ Yes - Sulfasalazine
    ❑ Yes - Tacrolimus (Prograf)
    ❑ Yes - Metronidazole (Flagyl) or ciprofloxacin (Cipro) (for pouchitis only)
    ❑ No

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076
Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.jhhc.com

14. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], corticosteroid [e.g., hydrocortisone [Entocort, Uceris], methylprednisolone, prednisone, cyclosporine [Sandimmune], mesalamine [Asacol, Lialda, Pentasa, Canasa, Rowasa], balsalazine, olsalazine, mercaptopurine [Purinethol], sulfasalazine, tacrolimus [Prograf], metronidazole/ciprofloxacin [for pouchitis only])? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

Section B: Crohn's Disease

15. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) indicated for the treatment of moderately to severely active Crohn's disease? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history of previous medications tried.***
If Yes, no further questions ❑ Yes ❑ No

16. Does the patient have fistulizing Crohn's disease? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation supporting diagnosis.*** *If Yes, no further questions* ❑ Yes ❑ No

17. Has the patient tried and had an inadequate response to at least one conventional therapy option? ***ACTION REQUIRED: If Yes, please attach patient's chart notes, medical record documentation, or claims history of previous medications tried, including response to therapy.***
If Yes, indicate below and no further questions.
❑ Yes - Sulfasalazine (Azulfidine, Sulfazine)
❑ Yes - Metronidazole (Flagyl)
❑ Yes - Ciprofloxacin (Cipro)
❑ Yes - Prednisone
❑ Yes - Budesonide (Entocort EC)
❑ Yes - Azathioprine (Azasan, Imuran)
❑ Yes - Mercaptopurine (Purinethol)
❑ Yes - Methotrexate intramuscular (IM) or subcutaneous (SC)
❑ Yes - Methylprednisolone (Solu-Medrol) (IV)
❑ Yes - Rifaximin (Xifaxan)
❑ Yes - Tacrolimus
❑ No

18. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], budesonide [Entocort EC], ciprofloxacin [Cipro], mercaptopurine [Purinethol], methylprednisolone [Solu-Medrol], methotrexate, metronidazole [Flagyl], prednisone, sulfasalazine [Azulfidine, Sulfazine], rifaximin [Xifaxan], tacrolimus)? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

Section C: Immune Checkpoint Inhibitor-Related Diarrhea or Colitis

19. Has the patient experienced an inadequate response, intolerance, or contraindication to systemic corticosteroids? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756